The $5.2bn impending merger between Pfizer and Anacor is expected to accelerate the marketing and commercialisation of Anacor’s atopic dermatitis pipeline candidate Crisaborole, according to a report by GlobalData.
Anacor’s Crisaborole was initially planned to be introduced in the US lone, but with Pfizer now on board the drug is planned to be launched globally across all the major markets resulting in a larger patient population for the drug.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
The report, titled ‘PharmaPoint:Atopic Dermatitis -Global Drug Forecast and Market Analysis to 2024‘, highlights that competition in the severe atopic dermatitis market will be stiff with the launch of Regeneron and Sanofi’s dupilumab in the second quarter of 2017.
However, the entry of Crisaborole is expected to be smooth as it will be targeted at the dormant mild-to-moderate atopic dermatitis market.
Although Crisaborole has the first-mover advantage in mild-to-moderate atopic dermatitis market, it may face competition from Otsuka’s pipeline candidate, which has been licensed by Medimetriks in collaboration with Knight Therapeutics.
With a proven safety and efficacy record in treating the paediatric patients, Crisaborole will be a significant drug for this demographic.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataPh.D. GlobalData’s immunology analyst Abhilok Garg said: "Pfizer now has the opportunity to build on the work of Anacor by utilising its existing relationships with paediatricians and primary care physicians, and its experience in markets outside of the US.
"Indeed, this insight could serve to aid the company in its development of topical Xeljanz."
Crisaborole’s entry into the US market and six other major markets including France, Germany, Italy, Spain, the UK and Japan is estimated to benefit approximately eight million patients by 2024, of which paediatric or adolescent patients will account for 60%.
